
In today’s ACT Brief, we examine why oncologists should lead trial discussions while AI supports patients, how site burden can be measured before it becomes risk, and how FDA approved Cosentyx and Wilserdly for two different conditions.
Mike Keens, VP of Operations at Anju Software, offers his insights into the current state of decentralized trials, the state of clinical trials technology and the near-future skill sets for clinical trials professionals.






